
    
      Study recruitment was stopped on April 9, 2015. This decision was taken for business reasons
      due to changes in the prioritization of the drug development portfolio. This decision was not
      as a result of any evolving safety, efficacy issue or changes in the risk:benefit assessment
      of this product or regulatory interactions.
    
  